The FDA’s approval of GSK’s new malaria drug Tafenoquine (Krintafel) provokes a mixed response and a research team from the ANU and The University of Queensland make a ‘small fragment of human protein’ that kills the microbial parasite that causes malaria.
A rebrand of the existing Malaria Minute podcast, the Johns Hopkins Malaria Minute shares important advances in malaria research in 60 seconds.
Researchers detail the extent of antimalarial drug resistance around the world, considering its implications for the WHO's Global Technical Strategy for Malaria.
Researchers reveal the importance of antibody affinity and dissociation constant in parasite neutralisation.